

Individual Laboratory Report - Lab 3538

BREAST CANCER (AKT pathway) [Tissue] | 2025

SUMMARY OF YOUR PERFORMANCE IN THIS EQA

Assessment Category	Performance (mean score) ¹
Genotyping	1.93
Interpretation	1.83
Patient Identifiers & Clerical Accuracy	2.00
EQA Result (PASS or POOR)	PASS

CASE SPECIFIC FEEDBACK

Case 1

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0) Minor HGVS error e.g. missing brackets around the protein or p. inside brackets (0)
Interpretation	1.75	Failure to state that the inhibitor therapy is given in combination with specific hormone therapy (0.25) Please avoid the use of specific drug names and refer to the drug class (0)
Patient Identifiers & Clerical Accuracy	2.00	All essential patient identifiers present and no significant clerical errors (0)

Key: Green (Pass), Red (Poor performance), NRS (no results submitted), WDS (withdrew from scheme)

² Maximum score is 2.00

³ Deductions from the maximum score

EMQN CIC is an incorporated Community Interest Company registered in England and Wales (registration no: 12020789), which provides external quality assessment schemes for genomic diagnostic testing laboratories. EMQN is a UKAS accredited proficiency testing provider, No. 4367 and our registered address is Third Floor, ICE Building, 3 Exchange Quay, Salford, M5 3ED, United Kingdom.

Email: office@emqn.org Web: <https://www.emqn.org/>

3538



4367

Case 2

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	1.80	Minor HGVS error e.g. missing brackets around the protein or p. inside brackets (0) Reference sequence is missing / incorrect / inconsistent (0.2) Reference sequence version / transcript number is missing / incorrect / inconsistent (0)
Interpretation	2.00	Please avoid the use of specific drug names and refer to the drug class (0)
Patient Identifiers & Clerical Accuracy	2.00	All essential patient identifiers present and no significant clerical errors (0)

Case 3

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0) Minor HGVS error e.g. missing brackets around the protein or p. inside brackets (0) Exons 10 and 21 of PIK3CA, according to Ensembl Transcript ID: ENST00000263967.4, RefSeq: NM_006218.4, are usually designated as coding exons 9 and 20, respectively, since the entire exon 1 is an untranslated region.
Interpretation	1.75	Failure to state that the inhibitor therapy is given in combination with specific hormone therapy (0.25) Please avoid the use of specific drug names and refer to the drug class (0)
Patient Identifiers & Clerical Accuracy	2.00	All essential patient identifiers present and no significant clerical errors (0)

General Comments
3-letter amino acid codes are preferred by HGVS. A semi-colon is not required between the cDNA and protein description.

This Individual Laboratory Report should be read in conjunction with scheme summary report.

Thank you for participating in this year's EQA, we look forward to you participating again next year.

Report approved and authorised by Simon Patton (22 January 2026) on behalf of EMQN.



Dr. Simon Patton (CEO)

Key: ¹ **Green** (Pass), **Red** (Poor performance), NRS (no results submitted), WDS (withdrew from scheme)

² Maximum score is 2.00

³ Deductions from the maximum score

3538

EMQN CIC is an incorporated Community Interest Company registered in England and Wales (registration no: 12020789), which provides external quality assessment schemes for genomic diagnostic testing laboratories. EMQN is a UKAS accredited proficiency testing provider, No. 4367 and our registered address is Third Floor, ICE Building, 3 Exchange Quay, Salford, M5 3ED, United Kingdom.

Email: office@emqn.org Web: <https://www.emqn.org/>

